Everything below concerns somatotroph. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
=== As an invasive species === Although listed as an invasive species in several countries, one source reports that M. oleifera has "not been observed invading intact habitats or displacing native flora", so "should be regarded at present as a widely cultivated species with low invasive potential."
These transformations set the stage for the introduction of both epoxide groups, which were formed with high levels of diastereoselectivity based on the principles of macrocyclic stereocontrol. The first epoxide was introduced via nucleophilic epoxidation of the enone using potassium hydride and tert-butylhydroperoxide; this led to the formation of a 4:1 mixture of diastereomeric epoxides, favoring the desired isomer in which attack had occurred from the peripheral face of the enone. At this stage, the ketone was transformed into the second epoxide group using the Johnson-Corey-Chaykovsky reaction; notably, the product was formed as a single diastereomer, again due to initial peripheral attack of the dimethylsulfonium methylide nucleophile on the ketone. Subsequent removal of the TBS protecting group and Sarett oxidation of the resulting secondary alcohol completed the total synthesis of racemic periplanone B.
== F == familial Mediterranean fever - farnesol dehydrogenase - Fat storage-inducing transmembrane protein 2 - FDC-SP - FHIPEP protein family - fibroblasts - fluorescence in situ hybridization -fluorophore-assisted carbohydrate electrophoresis - footprinting - formylmethanofuran dehydrogenase - Fragile site, folic acid type, rare, fra(2)(q13) - Fragile X syndrome - frameshift mutation - fructose 5-dehydrogenase - fucoidanase - fungal fruit body lectin family - fusion protein -
=== International regulation === Under the framework of the Convention on Certain Conventional Weapons, states have discussed lethal autonomous weapon systems since 2014. In 2016, the treaty's states parties established an open-ended Group of Governmental Experts on Lethal Autonomous Weapons Systems to continue those discussions. The discussions have addressed international humanitarian law, accountability, possible prohibitions and regulations, and the extent of human control required over AI-enabled weapons.
Sources: en.wikipedia.org
The presence of ethanol can lead to the formations of non-lamellar phases also known as non-bilayer phases. Ethanol has been recognized as being an excellent solvent in an aqueous solution for inducing non-lamellar phases in phospholipids. The formation of non-lamellar phases in phospholipids is not completely understood, but it is significant that this amphiphilic molecule is capable of doing so. The formation of non-lamellar phases is significant in biomedical studies which include drug delivery, the transport of polar and non-polar ions using solvents capable of penetrating the biomembrane, increasing the elasticity of the biomembrane when it is being disrupted by unwanted substances (viruses, bacteria, solvents, etc.) and functioning as a channel or transporter of biomaterial.
=== Examples === A RING (Really Interesting New Gene) domain binds the E2 conjugase and might be found to mediate enzymatic activity in the E2-E3 complex An F-box domain (as in the SCF complex) binds the ubiquitinated substrate. (e.g., Cdc 4, which binds the target protein Sic1; Grr1, which binds Cln). A HECT domain, which is involved in the transfer of ubiquitin from the E2 to the substrate.
Adopting continuous plate-bending elements, interchanging the derivative degrees-of-freedom and changing the sign of the appropriate one gives many families of stream function elements. Taking the curl of the scalar stream function elements gives divergence-free velocity elements. The requirement that the stream function elements be continuous assures that the normal component of the velocity is continuous across element interfaces, all that is necessary for vanishing divergence on these interfaces. Boundary conditions are simple to apply. The stream function is constant on no-flow surfaces, with no-slip velocity conditions on surfaces. Stream function differences across open channels determine the flow. No boundary conditions are necessary on open boundaries, though consistent values may be used with some problems. These are all Dirichlet conditions. The algebraic equations to be solved are simple to set up, but of course are non-linear, requiring iteration of the linearized equations. Similar considerations apply to three-dimensions, but extension from 2D is not immediate because of the vector nature of the potential, and there exists no simple relation between the gradient and the curl as was the case in 2D.
=== Works cited === Ito, Koji (2020-08-31). "Review of the health benefits of habitual consumption of miso soup: focus on the effects on sympathetic nerve activity, blood pressure, and heart rate". Environmental Health and Preventive Medicine. 25 (1) 45. Bibcode:2020EHPM...25...45I. doi:10.1186/s12199-020-00883-4. PMC 7461326. PMID 32867671. Ichikawa, Tomomi (2020-03-25). "若年女性における排便状況と食事からの発酵食品摂取の関係" [A Study of the Relationship between Constipation Assessment and the Intake of Fermented Foods in the Diet of Young Women]. Journal of the Faculty of Human Life Studies (in Japanese). 7: 17–21. Archived from the original on 2021-08-05. Retrieved 2020-10-03.
== Occurrence == One or more bound protons are present in the nucleus of every atom. Free protons are found naturally in a number of situations in which energies or temperatures are high enough to separate them from electrons, for which they have some affinity. Free protons occur occasionally on Earth: thunderstorms can produce protons with energies of up to several tens of megaelectronvolt. Free protons exist in plasmas in which temperatures are too high to allow them to combine with electrons. Free protons of high energy and velocity make up 90% of cosmic rays, which propagate through the interstellar medium. Free protons are emitted directly from atomic nuclei in some rare types of radioactive decay. Protons also result (along with electrons and antineutrinos) from the radioactive decay of free neutrons, which are unstable.
Sources: en.wikipedia.org
=== Identifying Translated mRNA Regions === By using specific drugs, ribosome profiling can identify initiating regions of mRNA, elongating regions, and areas of translation stalling. Initiating regions can be detected by adding harringtonine or lactidomycin to prevent any further initiation. This allows the starting codon of the mRNAs throughout the cell lysate to be analyzed, which has been used to determine non-AUG sequences that do initiate translation. The other elongating regions can be detected by adding antibiotics like cycloheximide that inhibit translocation, chloramphenicol that inhibits transfer of peptides within the ribosome, or non-drug means like thermal freezing. These elongation freezing methods allow for the kinetics of translation to be analyzed. Since multiple ribosomes can translate a single mRNA molecule to speed up the translation process, RiboSeq demonstrates the protein coding regions within the mRNA and how quickly this is done depending on the mRNA being sequenced. This also allows for ribosome profiling to show pause sites within the transcriptome at specific codons. These sites of slow or paused translation are demonstrated by an increase in ribosome density and these pauses can link specific proteins with their roles within the cell.
=== Special Counsel to Buddy Roemer === In 1988, Kennedy became special counsel to Governor Buddy Roemer. In 1991, he was also appointed secretary to the governor's cabinet and served in both posts until 1992. Roemer tasked Kennedy with helping him pass two key priorities: tort and campaign finance reforms. Roemer instructed Kennedy to draft the Louisiana Products Liability Act, a bill that aimed to set forth four clear legal theories by which manufacturers could be held liable for damage their products caused. The new code also clarified what counted as "unreasonably dangerous" to help make potential sources of liability more predictable to both businesses and buyers with claims. Roemer then tasked Kennedy with building support for passing the legislation. As part of his advocacy, Kennedy published a law review article titled "A Primer on the Louisiana Products Liability Act". He argued that the Products Liability Act would "bring added clarity, precision and certainty to Louisiana's products liability doctrine" and "strike an equitable balance between the right of a claimant who is injured in a product-related accident to just compensation and the right of the product's manufacturer to be judged fairly." Kennedy also delivered public testimony before the Louisiana House Committee on Civil Law and Procedure in support of the bill, saying that the bill "provides for a state-of-the-art defense for manufacturers." The Louisiana legislature enacted the Louisiana Products Liability Act in 1988.
Molomo described the Selous Scouts in 2009 as "a terrorist unit within the Rhodesian security forces". Piers Brendon wrote in 2010 that "the Selous Scouts committed the worst atrocities" of any Rhodesian unit. Ian Martinez has written that the Selous Scout's killings of prisoners and use of chemical and biological weapons were war crimes.
As of May 2026, it is in preregistration for Freidreich's ataxia, phase 3 clinical trials for mitochondrial disorders, phase 2/3 trials for epilepsy, and phase 2 trials for Leigh disease, methylmalonic acidemia, noise-induced hearing loss, Parkinson's disease, and Rett syndrome, whereas no recent development has been reported for Tourette's syndrome.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
Reconstituted solutions are kept cold and used within the period stated on the label or certificate. Repeated warming and cooling cycles should be avoided because they encourage aggregation and gradual loss of potency.